Lumizyme
(Alglucosidase alfa)ApprovedProtein / enzyme
Alglucosidase alfa is used to treat Pompe disease, a rare genetic disorder where the body cannot break down a sugar called glycogen, causing it to build up in muscles and weaken them over time.[2] Lumizyme is currently approved and in use across 4 indications[4].[1]
Lumizyme is one of 54 small molecule programs targeting Glycogen storage disease due to acid maltase deficiency. It is currently in Approved.
4
Indications
21
Total Trials
3
Active Trials
53
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
79 competitors in Growth
#DrugCompanyPhaseTrials
1Growth Hormone
PfizerPhase 3
Lumizyme
GGenzyme, a Sanofi Company
Approved
Neo-Synephrine
EExela Pharma Sciences, LLC.
Phase 3
Recombinant Human Growth Hormone
Changchun GeneScience Pharmaceutical Co., Ltd.Phase 3
Piqray
NovartisPhase 2
Zyloprim
Jazz PharmaceuticalsPreclinical
Lenvima
EisaiPreclinical
Zolymbus
AbbViePreclinical
Aricept
EisaiPreclinical
TY-9591
TTYK Medicines, Inc
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pompe Disease13 trials
Show 10 more trials
Glycogen Storage Disease Type II2 trials
3 more indications
Regulatory
FDA Approval Timeline[5]
May 24, 2010
LUMIZYME
BLA BLA125291
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Lumizyme drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Alglucosidase alfa. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Modality
- Protein / enzyme[3]
- Highest Phase
- Approved[1]
- Company
- GGenzyme, a Sanofi Company